Dr. Brenda Porter, MD
Claim this profileStanford University
Studies Tuberous Sclerosis Complex
Studies Tuberous Sclerosis
3 reported clinical trials
3 drugs studied
Area of expertise
1Tuberous Sclerosis Complex
TSC2 positive
TSC1 positive
2Tuberous Sclerosis
TSC2 positive
TSC1 positive
Affiliated Hospitals
Clinical Trials Brenda Porter, MD is currently running
Carisbamate
for Lennox-Gastaut Syndrome
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Recruiting1 award Phase 315 criteria
Sirolimus
for Tuberous Sclerosis
This trial is testing sirolimus, a medication that helps control symptoms of Tuberous Sclerosis Complex (TSC), in infants. The goal is to prevent or delay seizures, which can impact long-term brain development. Sirolimus works by turning down the activity of a center in the body that doesn't function properly in TSC. Sirolimus has been studied for its potential to control seizures in pediatric patients with TSC and has shown promising results in improving seizure control.
Recruiting0 awards Phase 2
More about Brenda Porter, MD
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Brenda Porter, MD has experience with
- Placebo
- Sirolimus
- Carisbamate
Breakdown of trials Brenda Porter, MD has run
Tuberous Sclerosis Complex
Tuberous Sclerosis
Intellectual Disability
Epilepsy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brenda Porter, MD specialize in?
Brenda Porter, MD focuses on Tuberous Sclerosis Complex and Tuberous Sclerosis. In particular, much of their work with Tuberous Sclerosis Complex has involved TSC2 positive patients, or patients who are TSC1 positive.
Is Brenda Porter, MD currently recruiting for clinical trials?
Yes, Brenda Porter, MD is currently recruiting for 2 clinical trials in Palo Alto California. If you're interested in participating, you should apply.
Are there any treatments that Brenda Porter, MD has studied deeply?
Yes, Brenda Porter, MD has studied treatments such as Placebo, Sirolimus, Carisbamate.
What is the best way to schedule an appointment with Brenda Porter, MD?
Apply for one of the trials that Brenda Porter, MD is conducting.
What is the office address of Brenda Porter, MD?
The office of Brenda Porter, MD is located at: Stanford University, Palo Alto, California 94304 United States. This is the address for their practice at the Stanford University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.